Gland Pharma’s net profit declined 15 per cent to ₹194 crore in the first quarter ended June 30, 2023 compared to ₹229 crore in the corresponding quarter of the previous financial year. The total revenue of the Hyderabad-based company increased 51 per cent to ₹1,209 crore against ₹857 crore in the same period last year.
“The operating revenue for the quarter stood at ₹1209 crore a y-o-y growth of 41 per cent with an EBITDA of ₹298 crore The outcomes of the recently conducted US FDA inspections at three of our sterile facilities demonstrate our commitment to being a quality-focused and regulatory-compliant company,’‘ Srinivas Sadu, MD & CEO, Gland Pharma, said in a release.
NEW COO
The board has appointed Prakash Vithal Baliga as Chief Operating Officer effective August, 7, 2023. Baliga is a post-graduate in pharmacy with more than 30 years of experience in the pharmaceutical sector. He joined Gland Pharma in September, 2016 as Asst. Vice-President (Strategic Sourcing, Procurement and Commercial). He was elevated to the position of Vice-President in January, 2020. As Vice-President he has been leading sourcing, purchase, supply chain and commercial activities cross Gland Pharma operations.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.